A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1174-1180. doi: 10.1016/j.jaip.2018.10.032. Epub 2018 Nov 2.

Abstract

Background: Aspirin challenge and desensitization remains the criterion standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive.

Objective: To provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in 1 day.

Methods: Forty-four patients with a confirmed diagnosis of AERD, stable asthma, and baseline FEV1 value greater than or equal to 70% of predicted completed an oral aspirin challenge and desensitization protocol. The starting dose was 40.5 mg with escalating doses of aspirin (81, 162.5, 325 mg) at 90-minute intervals until symptoms were provoked. Desensitization was defined as tolerating a repeated administration of the provocative aspirin dose and at least 1 subsequent dose, bringing the total aspirin ingested during the in-clinic desensitization to 325 mg or more.

Results: Ninety-three percent of patients completed the challenge and desensitization in 1 day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over 2 days. One patient (2.3%) was discontinued from the protocol because of ongoing abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit, or hospitalization.

Conclusions: Patients with AERD on a stable asthma regimen and with a baseline FEV1 value greater than or equal to 70% can be safely desensitized to aspirin using a 90-minute dose escalation protocol, starting at a dose of 40.5 mg, and defining desensitization as tolerance of the repeated provocation dose and at least 1 subsequent aspirin dose, bringing total cumulative daily dose to 325 mg or more. This protocol can routinely be completed in 1 day.

Keywords: AERD; Aspirin challenge; Aspirin desensitization; Aspirin-exacerbated respiratory disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aspirin / administration & dosage*
  • Aspirin / adverse effects
  • Aspirin / immunology
  • Asthma, Aspirin-Induced / etiology
  • Asthma, Aspirin-Induced / immunology
  • Asthma, Aspirin-Induced / physiopathology
  • Asthma, Aspirin-Induced / therapy*
  • Chronic Disease
  • Cyclooxygenase Inhibitors / administration & dosage*
  • Cyclooxygenase Inhibitors / adverse effects
  • Cyclooxygenase Inhibitors / immunology
  • Desensitization, Immunologic / methods*
  • Dose-Response Relationship, Drug
  • Female
  • Forced Expiratory Volume
  • Humans
  • Male
  • Middle Aged
  • Nasal Polyps / chemically induced
  • Nasal Polyps / immunology
  • Nasal Polyps / therapy*
  • Rhinitis / chemically induced
  • Rhinitis / immunology
  • Rhinitis / therapy*
  • Sinusitis / chemically induced
  • Sinusitis / immunology
  • Sinusitis / therapy*

Substances

  • Cyclooxygenase Inhibitors
  • Aspirin